NASDAQ:LYEL

Lyell Immunopharma Stock Insider Trading

Healthcare > Biotechnology

Buy LYEL

*Your capital is at risk

$13.00

+0.370 (+2.93%)

At Close: Jun 24, 2026

Lyell Immunopharma Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 93.09. In total, the insiders bought 2.92M and sold 108.93K LYEL shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	93.09
● Buy	2.92M shares
● Sell	108.93K shares
57% Buy Activity Moderate Negative Correlation
Buy Signal Medium Confidence Mar 06, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 93.09. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 15, 2026 Sell	Common Stock J-Other	Innovative Cellular Therapeutics Holdings Ltd 10 Percent Owner	10% Owner	66 500 Value: $0
Jun 10, 2026 Buy	Option (right to buy) A-Award	Bachleda Mark Director	Director	9 250 Value: $122.3K
Jun 10, 2026 Buy	Option (right to buy) A-Award	Friedman Cathy Director	Director	9 250 Value: $122.3K
Jun 10, 2026 Buy	Option (right to buy) A-Award	Nabel Elizabeth G Director	Director	9 250 Value: $122.3K
Jun 10, 2026 Buy	Option (right to buy) A-Award	Rieflin William Jl Director	Director	9 250 Value: $122.3K
Jun 10, 2026 Buy	Option (right to buy) A-Award	Ramachandra Sumant Director	Director	9 250 Value: $122.3K
Jun 10, 2026 Buy	Option (right to buy) A-Award	Klausner Richard Director	Director	9 250 Value: $122.3K
Jun 10, 2026 Buy	Option (right to buy) A-Award	Brawley Otis W Director	Director	9 250 Value: $122.3K
Jun 10, 2026 Sell	Common Stock S-Sale	Shook David Chief Medical Officer	Officer	1 977 Value: $25.0K
May 18, 2026 Buy	Common Stock	Innovative Cellular Therapeutics Holdings Ltd 10 Percent Owner	10% Owner	0 Value: $0
May 11, 2026 Sell	Common Stock S-Sale	Bulis Veronica Sanchez Vp, Corporate Controller	Officer	217 Value: $4K
May 11, 2026 Sell	Common Stock S-Sale	Hill Stephen J. Chief Operating Officer	C-Suite Officer	89 Value: $2K
May 11, 2026 Sell	Common Stock S-Sale	Lee Gary K. Chief Scientific Officer	Officer	130 Value: $2K
May 11, 2026 Sell	Common Stock S-Sale	Seely Lynn President And CEO	CEO / President	388 Value: $7K
Mar 09, 2026 Buy	Common Stock J-Other	Shah Smital Insider	Other	0 Value: $0
Mar 09, 2026 Buy	Option (right to buy) A-Award	Shah Smital Chief Fin. And Bus. Officer	Officer	140 000 Value: $3.57M
Mar 06, 2026 Buy	Common Stock P-Purchase	Arch Venture Fund Xiii, L.p. 10 Percent Owner	10% Owner	488 090 Value: $12.5M
Mar 06, 2026 Buy	Common Stock P-Purchase	Arch Venture Partners Ix, Llc 10 Percent Owner	10% Owner	488 090 Value: $12.5M
Feb 11, 2026 Sell	Common Stock S-Sale	Seely Lynn President And CEO	CEO / President	7 455 Value: $174.4K
Feb 11, 2026 Sell	Common Stock S-Sale	Hill Stephen J. Chief Operating Officer	C-Suite Officer	1 236 Value: $28.9K
Feb 11, 2026 Sell	Common Stock S-Sale	Lee Gary K. Chief Scientific Officer	Officer	1 671 Value: $39.1K
Feb 10, 2026 Buy	Option (right to buy) A-Award	Hill Stephen J. Chief Operating Officer	C-Suite Officer	65 000 Value: $1.54M
Feb 10, 2026 Sell	Common Stock S-Sale	Hill Stephen J. Chief Operating Officer	C-Suite Officer	109 Value: $3K
Feb 10, 2026 Buy	Option (right to buy) A-Award	Lee Gary K. Chief Scientific Officer	Officer	50 000 Value: $1.19M
Feb 10, 2026 Buy	Common Stock A-Award	Bulis Veronica Sanchez Vp, Corporate Controller	Officer	8 750 Value: $207.5K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT LYELL IMMUNOPHARMA, INC.

Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate ...

Read Full Profile Here